Transcutaneous Vagus Nerve Stimulation (tVNS) for Treatment of Drug-Resistant Epilepsy: A Randomized, Double-Blind Clinical Trial (cMPsE02)

doi:10.1016/j.brs.2015.11.003

Brain Stimulation

Volume 9, Issue 3, May–June 2016, Pages 356-363

https://doi.org/10.1016/j.brs.2015.11.003 Get rights and content

Highlights

•
We compared active transcutaneous vagus nerve stimulation (tVNS) with a sham stimulation paradigm for treatment of drug-resistant epilepsy in a double-blind, randomized clinical trial.
•
Superiority of active tVNS vs. control tVNS could not be proven, but seizure frequency was significantly reduced in patients who completed the full active tVNS treatment period of 20 weeks.
•
Treatment adherence was high.
•
tVNS is a well tolerated treatment procedure.

Abstract

Background

Various brain stimulation techniques are in use to treat epilepsy. These methods usually require surgical implantation procedures. Transcutaneous vagus nerve stimulation (tVNS) is a non-invasive technique to stimulate the left auricular branch of the vagus nerve at the ear conch.

Objective

We performed a randomized, double-blind controlled trial (cMPsE02) to assess efficacy and safety of tVNS vs. control stimulation in patients with drug-resistant epilepsy.

Methods

Primary objective was to demonstrate superiority of add-on therapy with tVNS (stimulation frequency 25 Hz, n = 39) versus active control (1 Hz, n = 37) in reducing seizure frequency over 20 weeks. Secondary objectives comprised reduction in seizure frequency from baseline to end of treatment, subgroup analyses and safety evaluation.

Results

Treatment adherence was 84% in the 1 Hz group and 88% in the 25 Hz group, respectively. Stimulation intensity significantly differed between the 1 Hz group (1.02 ± 0.83 mA) and the 25 Hz group (0.50 ± 0.47 mA; p = 0.006). Mean seizure reduction per 28 days at end of treatment was –2.9% in the 1 Hz group and 23.4% in the 25 Hz group (p = 0.146). In contrast to controls, we found a significant reduction in seizure frequency in patients of the 25 Hz group who completed the full treatment period (20 weeks; n = 26, 34.2%, p = 0.034). Responder rates (25%, 50%) were similar in both groups. Subgroup analyses for seizure type and baseline seizure frequency revealed no significant differences. Adverse events were usually mild or moderate and comprised headache, ear pain, application site erythema, vertigo, fatigue, and nausea. Four serious adverse events were reported including one sudden unexplained death in epilepsy patients (SUDEP) in the 1 Hz group which was assessed as not treatment-related.

Conclusions

tVNS had a high treatment adherence and was well tolerated. Superiority of 25 Hz tVNS over 1 Hz tVNS could not be proven in this relatively small study, which might be attributed to the higher stimulation intensity in the control group. Efficacy data revealed results that justify further trials with larger patient numbers and longer observation periods.

Introduction

Epilepsy is a chronic neurological disorder characterized by recurring, unprovoked seizures, and affects about 50 million people worldwide [1]. About 1/3 of the patients do not become seizure free despite anticonvulsant drug treatment [2]. A minority of these patients can be cured by resective epilepsy surgery. For the remaining patients, various brain stimulation therapies are available, among which invasive vagus nerve stimulation (iVNS) is most frequently used. It requires implantation of a stimulator and an electrode which connects to the left vagal nerve. Long-term iVNS decreased seizure frequency during initial treatment by 24.5% to 28% [3], [4]. Seizure reduction increased over time up to 45% in several studies [5].

Transcutaneous vagus nerve stimulation (tVNS) is a newly developed method which intends to overcome the disadvantage of surgical implantation of the stimulation device [6]. The auricular branch of the vagus nerve (ABVN) supplies the cymba conchae [7]. The ABVN can be stimulated using an external device with a bipolar electrode attached to the skin of the left ear conch (Fig. 1). Pilot studies showed responder rates and mean seizure reduction of up to 55% [8], [9].

We performed a randomized, double-blind controlled trial (cMPsE02) to assess efficacy and safety of 20 weeks of tVNS in patients with drug-resistant epilepsy. The primary objective of this study was to demonstrate superiority of add-on therapy with “high-level” tVNS (stimulation frequency 25 Hz) versus active control (“low-level” tVNS, 1 Hz) in reducing seizure frequency.

Section snippets

Patients

Patients between 18 and 65 years of age were eligible for this study if they suffered from epilepsy with focal and/or generalized seizures, had ≥3 seizures per month and not more than 21 consecutive seizure-free days. Seizure frequency was assessed retrospectively prior to screening and prospectively during the baseline period. Patients had to be on a stable regimen of ≤3 antiepileptic drugs (AEDs) for at least 5 weeks prior to study enrollment. This AED regimen had to be maintained throughout

Results

Seventy-six patients were randomized to the high-level (n = 37) or low-level (n = 39) stimulation group. The study was completed by 58 patients (76 %); 8 patients of the 1 Hz group and 10 patients of the 25 Hz group prematurely discontinued the study. Patient disposition and reasons for study discontinuation are shown in Fig. 2. Demographic and baseline data were comparable between both groups (Table 1).

Baseline seizure frequency was 50.4 ± 101.7 seizures in the 1 Hz group and 62.1 ± 147.6 in

Discussion

The null hypothesis (no difference between seizure frequencies in both treatment groups) could not be rejected. Hence, superiority of 25 Hz tVNS over 1 Hz tVNS could not be proven in this study. The considerable seizure reduction rate of 23.4% within the 25 Hz group (as compared to an increase in seizure frequency of 2.9% in the control group) did not reach significance due to the very high variability in seizure frequencies in both groups.

However, seizure frequency decreased significantly by

Conclusions

Transcutaneous vagus nerve stimulation is a well tolerated procedure with high treatment compliance rates in patients with drug-resistant epilepsy. Although superiority of 25 Hz tVNS over 1 Hz tVNS could not be proven in this study, efficacy data revealed results that justify further trials with larger patient numbers. Since treatment effect appeared to set in after 20 weeks of treatment, longer observation periods are desirable in upcoming studies. Future trials should focus on comparison of

References (17)

P. Boon et al.
Electrical stimulation for the treatment of epilepsy
Neurother
(2009)
HeW. et al.
Transcutaneous auricular vagus nerve stimulation as a complementary therapy for pediatric epilepsy: a pilot trial
Epilepsy Behav
(2013)
G.A. Baker et al.
The development of a seizure severity scale as an outcome measure in epilepsy
Epilepsy Res
(1991)
P.M. Kreuzer et al.
Feasibility, safety and efficacy of transcutaneous vagus nerve stimulation in chronic tinnitus: an open pilot study
Brain Stimul
(2014)
S. Shorvon et al.
Sudden unexpected death in epilepsy
Lancet
(2011)
M.J. Brodie et al.
Commission on European Affairs: appropriate standards of epilepsy care across Europe. ILEA
Epilepsia
(1997)
P. Kwan et al.
Early identification of refractory epilepsy
N Engl J Med
(2000)
A. Handforth et al.
Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial
Neurology
(1998)

There are more references available in the full text version of this article.

Cited by (182)

Transcutaneous auricular vagus nerve stimulation therapy in patients with cognitively preserved structural focal epilepsy: A case series report
2024, Brain and Development
Transcutaneous auricular vagus nerve stimulation (taVNS) was performed in two patients suffering structural focal epilepsy with preserved intellectual ability to show the feasibility of taVNS for specific patient groups.
Patient 1 was a 24-year-old woman with frontal lobe epilepsy who had weekly hyperkinetic seizures despite multiple anti-seizure medications. Patient 2 was a 27-year-old woman with parietal lobe epilepsy and focal cortical dysplasia in the vicinity of the lipoma in the corpus callosum. She experienced weekly focal-impaired awareness seizures even with anti-seizure medication. taVNS was applied to the left earlobe of both patients at 1.5 mA, 25 Hz, 250 μs pulse width, and 30 s stimulation with 30 s rest for 4 h per day. Over an 8-week baseline and 20 weeks of stimulation, the rate of reduction in seizure frequency was evaluated, along with quality-of-life using the Short-Form 36-Item Health survey.
At baseline, we measured up to 11 and 12 focal seizures per week in Patient 1 and 2, respectively, with both patients achieving seizure freedom after 4 and 20 weeks taVNS, respectively. Patient 1 and 2 were observed for 18 and 14 months, respectively, including the clinical trial and follow-up observation period. Quality-of-life ratings increased in both patients, and no significant adverse events occurred during the study period. During the maintenance period after 20 weeks, seizures remained absent in Patient 1, and seizures remained reduced in Patient 2.
Our results demonstrate that taVNS may be a promising tool for structural focal epilepsy with preserved cognitive function. A multicenter double-blind clinical trial is needed to confirm the role of taVNS as an anti-seizure tool.
Transcutaneous Auricular Vagus Nerve Stimulation (ta-VNS) for Treatment of Drug-Resistant Epilepsy: A Randomized, Double-Blind Clinical Trial
2023, Neurotherapeutics
This study explored the efficacy and safety of transcutaneous auricular vagus nerve stimulation (ta-VNS) in patients with epilepsy. A total of 150 patients were randomly divided into active stimulation group and control group. At baseline and 4, 12, and 20 weeks of stimulation, demographic information, seizure frequency, and adverse events were recorded; at 20 weeks, the patients underwent assessment of quality of life, Hamilton Anxiety and Depression scale, MINI suicide scale, and MoCA scale. Seizure frequency was determined according to the patient's seizure diary. Seizure frequency reduction > 50% was considered effective. During our study, the antiepileptic drugs were maintained at a constant level in all subjects. At 20 weeks, the responder rate was significantly higher in active group than in control group. The relative reduction of seizure frequency in the active group was significantly higher than that in the control group at 20 weeks. Additionally, no significant differences were shown in QOL, HAMA, HAMD, MINI, and MoCA score at 20 weeks. The main adverse events were pain, sleep disturbance, flu-like symptoms, and local skin discomfort. No severe adverse events were reported in active and control group. There were no significant differences in adverse events and severe adverse events between the two groups. The present study showed that ta-VNS is an effective and safe therapy for epilepsy. Furthermore, the benefit in QOL, mood, and cognitive state of ta-VNS needs further validation in the future study although no significant improvement was shown in this study.
Evaluation of the Modulation Effects Evoked by Different Transcutaneous Auricular Vagus Nerve Stimulation Frequencies Along the Central Vagus Nerve Pathway in Migraine: A Functional Magnetic Resonance Imaging Study
2023, Neuromodulation
Transcutaneous auricular vagus nerve stimulation (taVNS) is a promising treatment option for migraines. This study aims to investigate the modulation effects of different taVNS frequencies along the central vagus nerve pathway in migraineurs.
Twenty-four migraineurs were recruited for a single-blind, crossover magnetic resonance imaging (MRI) study. The study consisted of two taVNS MRI scan sessions, in which either 1-Hz or 20-Hz taVNS was applied in a random order. Seed-based static and dynamic functional connectivity (FC) analyses were performed using two key nodes of the vagus nerve pathway, the nucleus tractus solitarius (NTS) and the locus coeruleus (LC).
Static FC (sFC) analysis showed that 1) continuous 1-Hz taVNS resulted in an increase of NTS/LC–occipital cortex sFC and a decrease of NTS-thalamus sFC compared with the pre–1-Hz taVNS resting state, 2) continuous 20-Hz taVNS resulted in an increase of the LC–anterior cingulate cortex (ACC) sFC compared with the pre–20-Hz taVNS resting state, 3) 1-Hz taVNS produced a greater LC-precuneus and LC–inferior parietal cortex sFC than 20 Hz, and 4) 20-Hz taVNS increased LC-ACC and LC–super temporal gyrus/insula sFC in comparison with 1 Hz. Dynamic FC (dFC) analysis showed that compared with the pre-taVNS resting state, 1-Hz taVNS decreased NTS–postcentral gyrus dFC (less variability), 20-Hz taVNS decreased dFC of the LC–superior temporal gyrus and the LC–occipital cortex. Finally, a positive correlation was found between the subjects’ number of migraine attacks in the past four weeks and the NTS-thalamus sFC during pre-taVNS resting state.
1-Hz and 20-Hz taVNS may modulate the sFC and dFC of key nodes in the central vagus nerve pathway differently. Our findings highlight the importance of stimulation parameters (frequencies) in taVNS treatment.
Bibliometric analysis of vertigo-related histopathology, vestibular rehabilitation, physical rehabilitation, and Chinese and Western medical treatments
2024, Chinese Journal of Tissue Engineering Research
Heart rate variability and cold-induced vascular dilation after stimulation of two different areas of the ear: a prospective, single-blinded, randomized crossover study
2024, BMC Complementary Medicine and Therapies
Non-invasive vagus nerve stimulation and the motivation to work for rewards: A replication of Neuser et al. (2020, Nature Communications)
2024, Psychophysiology

View all citing articles on Scopus

¹: Both authors contributed equally.

View full text

Transcutaneous Vagus Nerve Stimulation (tVNS) for Treatment of Drug-Resistant Epilepsy: A Randomized, Double-Blind Clinical Trial (cMPsE02)

Highlights

Abstract

Background

Objective

Methods

Results

Conclusions

Introduction

Section snippets

Patients

Results

Discussion

Conclusions

Neurother

Epilepsy Behav

Epilepsy Res

Brain Stimul

Lancet

Commission on European Affairs: appropriate standards of epilepsy care across Europe. ILEA

Epilepsia

Early identification of refractory epilepsy

N Engl J Med

Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial

Neurology